Table 1.

Comparison of Baseline Characteristics

	Total (N=166)	Omega-3 (+) (N=30)	Omega-3 (−) (N=136)	P Value
Demographics
Age, y	57 (48, 65)	49 (40, 57)	58 (51,67)	<0.001*
Body mass index	30.0 (25.4, 36.2)	32.8 (28.1, 35.8)	29.9 (25.4, 36.2)	0.36
Male	137 (83%)	26 (87%)	111 (82%)	0.07
LVAD duration before the enrollment, d	20 (14, 32)	25 (5, 64)	20 (14, 28)	0.06
Destination therapy	145 (87%)	26 (87%)	119 (88%)	0.18
Device
Axial LVAD	100 (60%)	17 (57%)	83 (61%)	0.40
Centrifugal LVAD	66 (40%)	13 (43%)	53 (39%)	0.84
Temporary RVAD use	12 (7%)	2 (7%)	10 (7%)	0.90
Comorbidity
Ischemic cause	57 (34%)	7 (23%)	50 (37%)	0.22
Hypertension	95 (57%)	18 (60%)	77 (57%)	0.45
Diabetes mellitus	58 (35%)	8 (27%)	50 (37%)	0.20
Atrial fibrillation	60 (36%)	10 (33%)	50 (37%)	0.45
History of stroke	28 (17%)	3 (10%)	25 (18%)	0.20
History of ventricular tachyarrhythmia	61 (37%)	10 (33%)	51 (38%)	0.42
Hemoglobin, g/dL	9.56±1.25	9.80±1.35	9.50±1.23	0.32

LVAD indicates left ventricular assist device; and RVAD, right ventricular assist device.

^*P<0.05 by unpaired t test or Mann-Whitney U test.